Core Viewpoint - Brother Technology (002562) has received approval from the National Medical Products Administration for the iodine contrast agent injection, Iohexol, allowing for its official market launch in China, which enhances the company's competitiveness in the contrast agent sector [1] Group 1 - Brother Technology's wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Iohexol injection [1] - Iohexol injection is primarily used for various types of angiography and CT enhancement examinations, characterized by low viscosity and good safety [1] - The approval for Iohexol injection marks a significant step for Brother Pharmaceutical in commercializing this product and expanding its iodine contrast agent product line [1]

Core Viewpoint - Brother Technology (002562.SZ) announced that its wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received the drug registration certificate for Iohexol injection from the National Medical Products Administration, allowing for commercial sales in China [1] Group 1 - The Iohexol injection is primarily used for various types of imaging procedures, including cardiovascular, peripheral artery, venous, coronary, cerebral, urinary tract, spinal, and joint imaging, as well as CT enhancement [1] - The product is characterized by low viscosity and good safety, which are significant advantages in its application [1] - The approval for Iohexol injection marks a significant step for Brother Pharmaceutical in commercializing this product, enhancing its product line of iodine contrast agents and increasing its competitiveness in the contrast agent market [1]

Core Viewpoint - Brother Technology (002562.SZ) announced that its subsidiary, Brother Pharmaceutical, has recently received the Drug Registration Certificate issued by the National Medical Products Administration for Iopamidol Injection, which is primarily used for various types of angiography and CT enhancement examinations [1] Group 1 - The Drug Registration Certificate numbers are 2025S02892 and 2025S02893 [1] - Iopamidol Injection is utilized for cardiovascular angiography, peripheral artery angiography, venous angiography, coronary angiography, cerebrovascular angiography, urinary tract angiography, spinal cord angiography, and joint angiography [1] - The product is characterized by low viscosity and good safety [1]

规格：100ml：37g（I）、50ml：18.5g（I） 注册分类：化学药品4类 证券代码：002562 证券简称：兄弟科技 公告编号：2025-057 兄弟科技股份有限公司 关于全资子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 兄弟科技股份有限公司（以下简称"公司"）全资子公司浙江兄弟药业有限公司（以下简 称"兄弟药业"）于近日收到国家药品监督管理局核准签发的《药品注册证书》（证书编号： 2025S02892、2025S02893），现将相关情况公告如下： 一、药品基本信息 药品名称：碘帕醇注射液 剂型：注射剂 本次碘帕醇注射液获批上市，标志着本产品可以在中国境内正式上市销售，为兄弟药业 对该产品进行商业化销售提供了资质保障，同时将进一步丰富公司的碘造影剂产品线、提升 公司在造影剂领域的市场竞争力。 由于医药行业的特点，药品的生产、销售情况受公司销售推广、国家政策、市场环境变 化等因素影响，存在不确定性，敬请广大投资者谨慎决策，注意投资风险。 四、备查文件 药品上市许可持有人：浙江兄弟药业有限公司 药品批准文号：国药准字H2 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the iodine-pamidronate injection registration certificate, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The iodine-pamidronate injection is primarily used for various imaging procedures, including cardiovascular, peripheral artery, venous, coronary, cerebral, urinary tract, spinal, and joint imaging, as well as CT enhancement [1] - The product is characterized by low viscosity and good safety profile, making it a favorable option in the medical imaging market [1] Group 2: Market Inclusion - The iodine-pamidronate injection has been included in the National Medical Insurance Class A directory, which enhances its market accessibility and potential sales [1] - It has also been incorporated into the seventh batch of the National Drug Centralized Procurement directory, indicating a strategic move to streamline procurement processes and potentially reduce costs [1]

Group 1 - Brother Technology's wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received the drug registration certificate for "Iohexol Injection" from the National Medical Products Administration [1] - As of January to June 2025, Brother Technology's revenue composition is 97.09% from fine chemicals and 2.91% from other segments [1] - The current market capitalization of Brother Technology is 7.8 billion yuan [1]

Group 1 - The core point of the article is that Brother Technology has released an earnings forecast indicating a significant increase in net profit, projected to grow by 173.92% year-on-year [1] Group 2 - Only one stock, Brother Technology, has issued an earnings forecast this week [1] - The substantial profit increase highlights potential growth opportunities within the company [1]

Market Performance - The PEEK materials concept declined by 2.65%, ranking among the top losers in the concept sector as of the market close on September 19 [1] - Key stocks within the PEEK materials sector included Jinfa Technology, which hit the daily limit down, and other notable decliners such as Changying Precision, Guoen Co., and Zhongyan Co. [1] - Conversely, eight stocks within the sector saw price increases, with Taihe Technology, Brother Technology, and China Jushi leading the gains at 3.43%, 2.96%, and 2.29% respectively [1] Capital Flow - The PEEK materials sector experienced a net outflow of 3.634 billion yuan, with 32 stocks seeing net outflows and seven stocks exceeding 100 million yuan in outflows [1] - Jinfa Technology led the outflows with a net outflow of 1.663 billion yuan, followed by Changying Precision, Guangqi Technology, and Shuanglin Co. with net outflows of 455 million yuan, 368 million yuan, and 242 million yuan respectively [1] - On the other hand, stocks such as Ningbo Huaxiang, Guoen Co., and Brother Technology saw net inflows of 71.36 million yuan, 51.19 million yuan, and 19.27 million yuan respectively [1][2] Sector Comparison - Among the concept sectors, the top gainers included photolithography machines at 2.09%, while the PEEK materials sector was among the top losers at -2.65% [1] - Other sectors with notable performance included civil explosives at 1.70% and lithium extraction from salt lakes at 1.11%, contrasting with the decline in the PEEK materials sector [1]

Group 1 - The company has completed sample submissions to major domestic PEEK manufacturers, with some clients passing the verification process [2] - The company encourages stakeholders to monitor its regular reports for specific business developments [2]

Summary of Key Points Core Viewpoint - Brother Technology's stock experienced a decline of 2.07% with a trading volume of 1.817 billion yuan and a turnover rate of 34.94% on the day, indicating significant trading activity and potential volatility in the stock price [2]. Trading Activity - The stock was listed on the Dragon and Tiger list due to its high turnover rate, with institutional investors net selling 19.7211 million yuan [2]. - The top five trading departments accounted for a total transaction volume of 329 million yuan, with a net selling amount of 82.5761 million yuan [2]. - Specific trading details show that five institutional special seats were involved, with total buying amounting to 93.4311 million yuan and selling amounting to 113 million yuan, resulting in a net sell of 19.7211 million yuan [2]. Fund Flow - The stock saw a net outflow of 190 million yuan in main funds, with large orders contributing to a net outflow of 88.7613 million yuan and big orders contributing to a net outflow of 101 million yuan [2]. - Over the past five days, the stock experienced a net inflow of 130 million yuan in main funds [2]. Historical Performance - In the past six months, the stock has appeared on the Dragon and Tiger list eight times, with an average price increase of 0.41% the day after being listed and an average increase of 2.35% over the following five days [2].